WEBULL

Perspective Therapeutics to Showcase New Cancer Treatment Data at Major Medical Conference

Benzinga · 1d ago

Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO-GI) Congress 2026 taking place from January 8 to 10, 2026 in San Francisco, CA as detailed below. ASCO-GI has announced that it will release further details for regular abstracts for the conference on January 5, 2026.

 

About [212Pb]VMT-α-NET

Perspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received prior radiopharmaceutical therapies (RPT). Updated interim data from the study, as of a data-cut off (DCO) date of September 12, 2025, were presented at the European Society of Medical Oncology (ESMO) Congress 2025, the 2025 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium, and the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

As of that DCO, safety findings based on 55 patients who had received at least one treatment showed [²¹²Pb]VMT-α-NET continued to demonstrate a favorable safety profile, with no dose-limiting toxicities (DLTs), treatment-related discontinuations, or Grade 4 or 5 treatment-emergent adverse events (TEAEs) reported.

Anti-tumor activity based on all patients in Cohort 1 and half of the patients enrolled in Cohort 2 as of the DCO:

  • Of these 25 patients, 20 (80%) remained progression-free. Eight patients had achieved confirmed responses per investigator-assessed RECIST v1.1, all of which occurred in Cohort 2.
  • All 23 patients in Cohort 2 had at least one tumor expressing SSTR2, and 16 showed SSTR2 expression in all of their tumors.
  • Among the 16 patients with SSTR2 expression in all of their tumors, seven (44%) achieved confirmed responses, and 14 (87.5%) remained progression-free and on study, with a median follow-up of 41 weeks.